Swiss National Bank’s NewAmsterdam Pharma NAMS Stock Holding History

Swiss National Bank’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.85M	Hold	88,900	–	–	﹤0.01%	1669
2025 Q4	$3.12M	Buy	88,900 +1,800	+2%	+$65.5K	﹤0.01%	1631
2025 Q3	$2.48M	Buy	87,100 +3,200	+4%	+$76.7K	﹤0.01%	1744
2025 Q2	$1.52M	Buy	83,900 +13,000	+18%	+$237K	﹤0.01%	1943
2025 Q1	$1.45M	Sell	70,900 -1,100	-2%	-$24.5K	﹤0.01%	1948
2024 Q4	$1.85M	Buy	72,000 +36,900	+105%	+$784K	﹤0.01%	1900
2024 Q3	$583K	Hold	35,100	–	–	﹤0.01%	2400
2024 Q2	$674K	Buy	+35,100	New	+$704K	﹤0.01%	2340

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Swiss National Bank's NAMS Position: Q1 2026 in Review

Swiss National Bank held its NewAmsterdam Pharma (NAMS) position steady in Q1 2026 at 88,900 shares worth $2.85M. The position accounts for ﹤0.01% of the portfolio, ranked #1669.

Swiss National Bank first reported a position in NAMS in Q2 2024 and has held it in 8 quarters since. The position peaked at $3.12M in Q4 2025. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

Swiss National Bank held 88,900 shares of NewAmsterdam Pharma worth $2.85M as of Q1 2026.
Swiss National Bank left its NewAmsterdam Pharma share count unchanged in Q1 2026.
NewAmsterdam Pharma made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1669 holding.
Swiss National Bank first reported a position in NewAmsterdam Pharma in Q2 2024 and has held it in 8 quarters since.
Swiss National Bank's NewAmsterdam Pharma position peaked at $3.12M in Q4 2025.
170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.